Overview

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Status:
Completed
Trial end date:
2018-12-17
Target enrollment:
Participant gender:
Summary
The main objectives of the study were to assess the effects of Obeticholic Acid (OCA) on serum alkaline phosphatase (ALP) and total bilirubin, together as a composite endpoint and on safety in participants with primary biliary cirrhosis (PBC).
Phase:
Phase 3
Details
Lead Sponsor:
Intercept Pharmaceuticals
Treatments:
Chenodeoxycholic Acid